Naxogin® [Nimorazole]
Pfizer
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Anti-protozoan, a derivative of 5-nitroimidazole. The mechanism of action is associated with a violation of the DNA structure of sensitive microorganisms.
Nimorazole is active against Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica, gram-negative anaerobic bacteria, incl. Bacteroides fragilis.
Indications
Infections caused by Trichomonas vaginalis.
Composition
| 1 tab. | |
| nimorazole | 500 mg |
| excipients: corn starch; methylcellulose; MCC; stearic acid | |
No customer reviews for the moment.
Dosage and Administration
Naxogin is taken orally after eating.
Trichomoniasis: for adults, 2 g once or 3 doses, 1 g every 12 hours (for example, in the morning, in the evening and the next morning) or 250 mg 2 times a day for 6 days. Children - 15 mg / kg per day, divided into 3 doses for 5-7 days. Amebiasis: for adults - 500 mg 2 times a day for 5-10 days; children - 20 mg / kg per day, divided into 2 doses for 5-10 days.
Giardiasis: Adults - 500 mg 2 times a day for 5-7 days; children - 15 mg / kg per day, divided into 2 doses for 5-7 days.
Infection caused by Gardnerella vaginalis: adults - 500 mg 2 times a day for 7 days or 2 g once.
Acute necrotizing gingivitis (Vincet gingivitis): adults - 500 mg 2 times a day for 2 days.
Adverse reactions
From the digestive system: nausea, heartburn, vomiting, gastralgia, abnormal liver function.
From the side of the central nervous system and peripheral nervous system: dizziness, drowsiness, polyneuropathy, paresthesias, exacerbation of mental diseases.
Allergic reactions: skin rash
Contraindications
CNS diseases, acute neurological diseases, pregnancy, renal / hepatic failure, lactation period, children's age, hypersensitivity to nitroimidazole derivatives.
Drug interactions
Ethanol increases the likelihood of side effects.
Pregnancy and Lactation
Nimorazole is contraindicated for use during pregnancy and lactation (breastfeeding).
Special instructions
The simultaneous treatment of sexual partners, even in the absence of symptoms of the disease in one of them, is recommended. During the period of treatment can not eat ethanol. After the end of treatment with bacteriological recovery, the clinical symptoms of inflammation may persist for several days.
- Brand name: Naxogin
- Active ingredient: Nimorazole
Studies and clinical trials of Nimorazole (Click to expand)
- Voltammetric behavior and measurement of nimorazole
- Interactions of radiation, Cyclophosphamide and Nimorazole in a C3H mammary carcinoma in vivo
- Pilot study of nimorazole as a hypoxic-cell sensitizer with the “chart” regimen in head and neck cancer
- Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya
- Analysis of the basic 5-nitroimidazole nimorazole in blood by reversed-phase high-performance liquid chromatography, and its application to pharmacokinetic studies in individual mice
- A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo
- The mutagenic action of nitroimidazoles I. Metronidazole, nimorazole, dimetridazole and ronidazole
- Treatment of head and neck cancer using CHART with nimorazole: phase I and I studies
- A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (Dahanca) protocol 5–85: Overgaard J, Hansen HS, Overgaard M, Basthold L, Berthelsen A, Specht L, Lindelov B, Jorgensen K Radioth Oncol 1998; 46 : 135–146
- Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial
- Nimorazole may increase the effect of phenprocoumon
- Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck
- Treatment of head and neck cancer with CHART and nimorazole: phase II study
- A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
- The Comparison of the Efficacy among Three Different Nimorazole Regimens in the Treatment of Bacterial Vaginosis
- The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists
- NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer
- Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85
- Activité des Nitroimidazoles sur Clostridium perfringens. CMI et CMB de cinq Antibiotiques : Metronidazole, Tinidazole, Ornidazole, Nimorazole et Ternidazole
- METRONIDAZOLE AND NIMORAZOLE COMPARED IN TRICHOMONAS
- Paromomycin + nimorazole is best for intestinal amoebiasis
8 other products in the same category:
arrow_upward